Latest news on Laboratorytalk categorised by supplier
Cisbio International
Address:
BP 84175 Bagnols/Ceze
30204
France
Telephone: (France) +33 4 66 79 67 05
http://www.htrf.com
Our RSS feed for news from Cisbio International
Request to receive our free email newsletter each week
Listing of all 14 news releases from Cisbio International:
HTRF Terbium platform for GPCR screening
These assays mark the first products in Cisbio's second-generation HTRF technology pipeline to incorporate the Lumi4-Tb cryptate for enhanced screening performance Brochure available
News from Cisbio International ( 9 April 2008)
Assay enables study of all kinases and ATPases
Assay measures the generation of ADP (Adenosine 5'-diphosphate), which is directly detected by a specific antibody labelled with Eu3+ cryptate and correlates with amount of phosphorylated substrate Brochure available
News from Cisbio International (17 January 2008)
Deal to speed development of new therapies
BellBrook Labs, a provider of high throughput screening tools for drug discovery, reports that Cisbio is adopting its Transcreener HTS assay platform as part of a technology licensing agreement Brochure available
News from Cisbio International ( 3 December 2007)
Lumi4 complexes are incorporated in Cisbio assays
Cisbio and Lumiphore Announce Partnership for New Product and Technology Development Incorporating Lumi4 Compounds. Brochure available
News from Cisbio International ( 8 October 2007)
Third symposium on HTRF in drug discovery
Cisbio international, a developer of HTRF technology for assay development and drug screening, says its third HTRF in Drug Discovery Symposium will be held 26-28 September 2007 in Sonoma, California Brochure available
News from Cisbio International (11 July 2007)
Kinase assay platform extended to Tyrosine enzymes
Cisbio international, a developer of HTRF technology and services used in assay development and drug screening, announced the launch of HTRF Kinease TK at the SBS Conference in Montreal, Canada Brochure available
News from Cisbio International (18 April 2007)
HTRF cell-based assays launched at SBS
Cisbio international announced the launch of three new HTRF cell-based assays at the 2006 SBS conference in Seattle, Washington Brochure available
News from Cisbio International (21 September 2006)
Expanded list of serine/threonine kinases
Cisbio international expands its list of serine/threonine kinases validated using HTRF Kinease; company's universal kinase assay platform now validated on 104 kinases Brochure available
News from Cisbio International (10 August 2006)
$1.9M grant by France's National Research Agency
Technical background article Will be used to fund the company's intracellular molecular imaging (IMI) project, one of 70 selected from 400 applications for funding in the area of biology and healthcare technological innovation Brochure available
News from Cisbio International ( 9 August 2006)
Assay for all labs focused on GPCR-based targets
Cisbio international announced the release of its second IP-One assay, IP-One Elisa, at the 4th Annual GPCR (G-Protein Coupled Receptors) Congress in Barcelona, Spain Brochure available
News from Cisbio International (25 May 2006)
Upstate and Cisbio announce launch of HTRF Kinease
New kits for rapid kinase assay development mark second product collaboration between the two companies Brochure available
News from Cisbio International (29 March 2006)
Assays incorporate small molecule organic dye
Optimisation of cyclic AMP (adenosine 3',5'-cyclic monophosphate) assay formats with d2 acceptor molecule complements existing assay to enhance G-protein coupled receptor (GPCR) platform Brochure available
News from Cisbio International (13 September 2005)
Assay development for GPCR-Gq screening
Homogeneous screening platform delivers precise and time-sensitive second messenger measurement, and also represents a novel functional means of precisely investigating GPCR mechanistics Brochure available
News from Cisbio International ( 8 June 2005)
First blood test for mesothelioma
Up until now, there have been no reliable serum tumour markers for mesothelioma, which means that diagnosis, screening and monitoring responses to treatment have been difficult Brochure available
News from Cisbio International (10 May 2005)
